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(LT), issues relating to the assessment of the liver allograft in
long-term survivors are becoming increasingly relevant.
Histological abnormalities are commonly present in late post-
transplant biopsies, including protocol biopsies from patients
who appear to be well with good graft function. Recurrent
disease is the commonest recognised cause of abnormal graft his-
tology, but may be modiﬁed by the effects of immunosuppression
or interactions with other graft complications, resulting in
complex or atypical changes. Other abnormalities seen in late
post-transplant biopsies include rejection (which often has dif-
ferent appearances to those seen in the post-transplant period),
de novo disease, ‘‘idiopathic’’ post-transplant hepatitis (IPTH)
and nodular regenerative hyperplasia. In many cases graft dys-
function has more than one cause and liver biopsy may help to
identify the predominant cause of graft damage. Problems exist
with the terminology used to describe less well understood pat-
terns of graft injury, but there is emerging evidence to suggest
that late rejection, de novo autoimmune hepatitis and IPTH may
all be part of an overlapping spectrum of immune-mediated
injury occurring in the late post-transplant liver allograft. Careful
clinico-pathological correlation is very important and the word-
ing of the biopsy report should take into account therapeutic
implications, particularly whether changes in immunosuppres-
sion may be indicated. This article will provide an overview of
the main histological changes occurring in long-term survivors
post-LT, focusing on areas where the assessment of late
post-transplant biopsies is most relevant clinically.Journal of Hepatology 20
Keywords: Liver transplantation; Liver biopsy; Late rejection; Recurrent disease;
de novo disease; Idiopathic post-transplant hepatitis; Tolerence.
Received 22 December 2010; received in revised form 11 March 2011; accepted 13
March 2011
⇑Address: Department of Cellular Pathology, Level-1, Queen Elizabeth Hospital
Birmingham, Mindelsohn Way, Edgbaston Birmingham B15 2WB, United King-
dom. Tel.: +44 (0) 121 371 3345.
E-mail addresses: s.g.hubscher@bham.ac.uk, stefan.hubscher@uhb.nhs.uk.
Abbreviations: LT, liver transplantation; IPTH, ‘‘idiopathic’’ post-transplant hepa-
titis; HCV, hepatitis C virus; AR, acute rejection; CP, central perivenulitis; CR, chr-
onic rejection; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis;
AIH, autoimmune hepatitis; FCH, ﬁbrosing cholestatic hepatitis; IFN, interferon;
PCH, plasma cell hepatitis; NAFLD, non-alcoholic fatty liver disease; GSTT-1, glut-
athione-S-transferase T1; BSEP, bile salt export pump; LFT, liver function test; ALT,
alanine transaminase; HEV, hepatitis E virus.by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Most of the main complications that occur during the early post-
transplant period can also be seen in late post-transplant biopsies
(>1 year post-LT) [1] (Table 1). However, there are important dif-
ferences in their relative frequency. Recurrent disease is the com-
monest recognised cause of late graft dysfunction [2]. By contrast,
acute and chronic rejection are uncommon at this time and may
have different histological features to those seen in the early
post-transplant period. A substantial proportion of biopsies
obtained >1 year post-LT show changes of uncertain aetiology –
examples include non-speciﬁc portal and/or lobular inﬂamma-
tion, unexplained (‘‘idiopathic’’) chronic hepatitis, and a range
of architectural and vascular changes, sometimes referred to as
‘‘hepatic structural abnormalities’’. Changes seen in late post-
transplant biopsies are often complex and reﬂect more than
one pathological process – histology may help to identify the
dominant cause of graft damage in such cases.
The prevalence and spectrum of histological changes that
have been reported in late post-transplant biopsies vary consid-
erably from centre to centre (Tables 2 and 3) [3–15]. The reason
for this variation is uncertain, but some of the likely factors are
summarised in Table 4. The original indication for transplantation
is clearly important. In centres where hepatitis C virus (HCV) cir-
rhosis is the main indication for transplantation, recurrent HCV
hepatitis is the commonest diagnosis in late post-transplant
biopsies. By contrast, in the paediatric population, where the
great majority of transplants are carried out for non-recurring
diseases, changes seen in late biopsies have to be attributed to
another cause. Not surprisingly, histological abnormalities are
more frequently seen when biopsies are taken to investigate
the cause of abnormal graft function. However, abnormal graft
histology has also been observed in long-term protocol biopsies
from 5% to 85% of adults (Table 2) and 32% to 97% of children
(Table 3) who are clinically well with normal liver biochemistry.
The prevalence of histological abnormalities increases with time.
Different approaches to immunosuppression may also account
for centre-speciﬁc differences – for example, it has been11 vol. 55 j 702–717
Table 1. Histological diagnoses in 1045 liver biopsies obtained >1 year post-transplant during a 5 year period (2004–2009) at the Liver Unit, Queen Elizabeth
Hospital, Birmingham. In biopsies where more than one pathological process appeared to be present, the biopsy was classiﬁed according to the main histological diagnosis.
Seventy two percent of the biopsies were obtained on a protocol basis, the other 28% were clinically indicated.
Main Diagnosis Number (%)  
of Cases  
Comments
Normal/near normal  152 (15) 
Rejection 82 (8) Many cases co-exist with other patterns of graft damage 
Biliary obstruction/ 
cholestasis 
11 (1 ) 
Chronic hepatitis 294 (28) 59 (6%) cases related to recurrent disease 
235  (22%) cases other/unknown cause 
Recurrent disease 211 (20) 
Other findings 295 (28) Fatty change, vascular/structural changes, fibrosis, siderosis 
JOURNAL OF HEPATOLOGYsuggested that a higher prevalence of unexplained inﬂammatory
changes in late biopsies may reﬂect low grade immune-mediated
injury occurring in centres where immunosuppression is pro-
vided with a ‘‘light hand’’ [16]. There are also potential problems
with the terminology used to describe changes of uncertain aeti-Table 2. The frequency and spectrum of histological abnormalities in late post-tran
basis. The majority of patients in these studies are adults.
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HBV, hepatitis B virus; HCV, hepatitis C virus; AIH, autoimmune hepatitis; PBC, primary
Journal of Hepatology 201ology in late biopsies. For example, late rejection (with hepatitis-
like features), de novo autoimmune hepatitis and ‘‘idiopathic’’
post-transplant hepatitis are generally regarded as distinct
entities. However, as will be discussed later, there is emerging
evidence to suggest that these are probably all part of ansplant liver biopsies obtained as protocol biopsies or on a clinically-indicated
rmal histology 
  
al 
LFTs  
 Raised 
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N/A Unexplained chronic hepatitis (33%), recurrent 
 N/A Non-specific hepatitis (45%), recurrent 
with:
chronic hepatitis-cause unknown 
rejection (3%), other (4%)
chronic viral hepatitis (12%), chronic viral 
other (2%)
(0.5-2%)
disease (23%), fatty liver disease (14%), 
disease (25%), steatosis (11%), siderosis (4%)
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Table 3. Histological ﬁndings in children undergoing liver biopsy >1 year post-transplant. All of these studies included biopsies that were obtained on a protocol basis,
with >50% of children having normal liver biochemistry at the time of biopsy.
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Centre  No of  
biopsies  
Length of  
follow-up  
Abnormal 
histology
73% 
32% at 1 year 
55% at 5 years 
69% at 10 years 
92% 
97% 
34% at 1 year 
48% at 3 years
65% at 5 years 
69% at 10 years 
Chronic rejection  (42%), centrilobular fibrosis 
(22%), biliary cirrhosis (4%), other (4%)
Chronic hepatitis ± fibrosis (64%), biliary 
fibrosis (2%), recurrent PSC (2%), other (2%) - 
Fibrosis (92%) - moderate/severe in 30% 
lymphocytic infiltration of variable severity (54%)
All protocol biopsies from children with normal LFTs
Fibrosis (97%), inflammation (70%)  
Fibrosis (69%) - at 10 years 
at 10 years
Frontiers in Liver Transplantationoverlapping spectrum of immune-mediated damage in the liver
allograft [17].
The extent to which protocol biopsies are obtained as part
of annual review has changed in recent years [18]. Whilst
most centres still carry out protocol biopsies in HCV-positive
patients, mainly to assess disease progression, the majority
have discontinued this practice in other allograft recipients.
However, recent studies have shown that histological abnor-
malities are not only frequently present in protocol biopsies
from patients with normal liver function tests (Tables 2 and
3), but also that they include changes that are potentially sig-
niﬁcant clinically, such as progressive graft ﬁbrosis [7,9,12,14].
Conversely, the ﬁnding of normal or near-normal graft histol-
ogy in a protocol biopsy may be useful in supporting the
decision to reduce immunosuppressive therapy, if this is clin-
ically indicated (e.g. in a person with renal impairment) [9],
and is also regarded as an important baseline assessment
for patients who may be tolerant to immunosuppression
weaning [19–23].Table 4. Factors inﬂuencing the histological assessment of late post-trans-
plant biopsies.
Nature of original liver disease
Indication for liver biopsy (protocol or clinically indicated)  
Duration of follow up
Type/amount of  immunosuppression used  
Diagnostic criteria/terminology  Late rejection
Acute rejection (AR)
Although the prevalence of acute rejection (AR) is declining,
around 20–40% of patients still have one or more episodes
requiring treatment with additional immunosuppression [24].
The majority of episodes still occur during the ﬁrst few weeks
of transplantation and typically present with predominantly
portal-based inﬂammation, which is associated with inﬂamma-
tion of bile ducts and portal venules [1]. Studies dating back
to the late 1980s have suggested that late AR may have differ-
ent histological features to early acute rejection [3,25,26] –704 Journal of Hepatology 201these include a predominantly mononuclear portal inﬂamma-
tory cell inﬁltrate (contrasting with the mixed population of
cells more typically seen in early AR), less severe inﬂamma-
tion of bile ducts and portal venules, more prominent inter-
face hepatitis (in some cases associated with periportal
ﬁbrosis), and more prominent lobular hepatitis [27,28]. Lobu-
lar inﬂammatory changes tend to be most prominent in cen-
trilobular regions and are often associated with foci of
centrilobular or bridging necrosis [29–37] – these changes
are collectively referred to as ‘‘central perivenulitis’’ (CP)
[30,37] and can occur in the absence of signiﬁcant portal
inﬂammation (‘‘isolated central perivenulitis’’) [29,30,37–39]
(Fig. 1). For example, in two recent studies isolated CP was
present in 22% of children biopsied >3 months post-LT [38]
and 28% of adults undergoing protocol biopsy >3 years post-
LT [39]. Hepatic venous endothelitis, which is typically seen
in association with CP in early acute rejection, is rarely con-
spicuous in late rejection. Grading of late rejection with fea-
tures of CP is often difﬁcult according to the conventional
Banff criteria, which require the presence of typical portal
tract changes of AR [40]. However, a system proposed by
the Banff Working Group for grading the severity of CP [30]
appears to have some value in predicting adverse outcomes
[39].1 vol. 55 j 702–717
Fig. 1. Late rejection presenting with features of severe central perivenulitis.
Liver biopsy 11 years post-transplant for PSC from a patient in whom there had
been a recent reduction in immunosuppression because of concerns about renal
impairment and suspected biliary sepsis. An autoantibody screen was negative.
(A) Prominent inﬂammation and conﬂuent necrosis are present in two adjacent
perivenular regions and are associated with central-central bridging necrosis. (B)
By contrast, a portal tract shows only mild inﬂammation not involving the bile
duct or portal vessels.
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Histological abnormalities are commonly present in late 
post-transplant biopsies from adult and paediatric liver 
allograft recipients. These include protocol biopsies from 
patients who appear to be clinically well with good graft 
function. 
Recurrent disease is the commonest recognized cause 
of abnormal graft histology in late biopsies from adults, 
but is very uncommon in the paediatric population. The 
features of recurrent disease may be modified by the 
effects of immunosuppression and interaction with other 
graft complications, resulting in changes that are 
complex and difficult to interpret. 
In cases where graft dysfunction has more than one 
possible aetiological factor (e.g. recurrent hepatitis C and 
rejection), liver biopsy may help to identify the main 
cause of graft damage. 
Problems exist with the terminology used to describe late 
inflammatory changes that are not obviously related to 
recurrent disease. Although late rejection (with “hepatitic 
features”), de novo autoimmune hepatitis and “idiopathic” 
post-transplant chronic hepatitis are generally regarded 
as distinct entities, there is emerging evidence to suggest 
that they may all be part of an overlapping spectrum of 
immune-mediated injury in the long-term liver allograft. 
Recent studies suggest that “idiopathic” chronic hepatitis 
is an important cause of late graft fibrosis, in some cases 
leading to cirrhosis, particularly in the paediatric 
population. Further studies are required to determine 
which patients with late graft hepatitis are likely to 
progress to fibrosis or cirrhosis and whether such 
patients may benefit from treatment with 
immunosuppression 
Further studies are also required to determine the role of 
protocol biopsies in identifying patients in whom 
immunosuppression can be safely reduced or withdrawn 
completely in the hope of achieving “operational 
tolerance”. 
The overall appearances of late AR may thus resemble those
seen in chronic viral or autoimmune hepatitis and late AR, there-
fore, needs to be distinguished from other causes of post-
transplant chronic hepatitis, including viral infection, autoim-
mune hepatitis (recurrent or de novo), and ‘‘idiopathic’’ post-
transplant hepatitis. In terms of clinical management, the most
important distinction concerns late AR and hepatitis C, which will
be discussed later. The other conditions presenting with graft
inﬂammation at this stage are all likely to have an allo/auto-
immune basis and should, therefore, beneﬁt from an increase in
immunosuppression. Late rejection with features of CP often
presents with raised transaminase levels, contrasting with the
cholestatic liver biochemistry that is more typically seen in earlyJournal of Hepatology 201portal-based AR [33,34,41]. It tends to be less responsive to
immunosuppression and is associated with an increased fre-
quency of adverse outcomes – these include further episodes of
acute rejection [36,42], progression to chronic rejection
[32,33,39,42–45], and the development of de novo autoimmune
hepatitis [39,43]. In some cases, CP may lead to the development
of centrilobular ﬁbrosis [38,39]. Recognition of these changes at
an early stage and instigation of appropriate immunosuppressive
therapy may prevent the development of more serious graft com-
plications such as progression to chronic rejection. Many cases of
late acute rejection appear to be related to suboptimal
immunosuppression [46,47], although this is not always the case
[48]. Treatment in such cases requires re-instigation of adequate
baseline immunosuppression in addition to high-dose corticoste-
roids, similar to the regimen used for treating early acute
rejection.1 vol. 55 j 702–717 705
Table 5. Summary of the main diseases (excluding neoplasms) that are thought to recur following liver transplantation.
Recurrent Disease Frequency  Histological Features     
(in biopsies >12 months post-transplant)
Comments  
Hepatitis B  <10  Chronic hepatitis (typically mild). 
Fibrosis now rarely more than mild in severity. 
High frequency in 1980s/early 1990s 
(15-85%). 
Incidence and clinical impact now 
greatly reduced by use of anti-viral 
therapy pre- and post-transplant. 
Hepatitis C  >90  Chronic hepatitis, typically resembling changes 
seen in the native liver. 
More severe cases may be associated  with 
prominent interface hepatitis ± confluent or 
bridging necrosis. 
Some cases have “autoimmune features” 
Progressive disease common - 20-50% 
cirrhotic by 5-10 years. 
Commonest indication for liver 
transplantation in many centres.  
Most cases result in graft damage, 
severity variable.  
Most frequent cause of late graft 
failure. 
Primary biliary 
cirrhosis (PBC) 
.sitignalohcsuotamolunargrocitycohpmyL05-02
Portal mononuclear inflammation-typically  
focal. May precede development of typical bile 
duct lesions by several years. 
Progressive disease associated with 
ductopenia and features of chronic 
cholestasis. Progression to cirrhosis rare. 
Most cases have mild/asymptomatic 
disease, frequently diagnosed on 
protocol biopsies.  
Rare cases (<1%) progress to graft 
failure 
Primary sclerosing 
cholangitis (PSC) 
revilnineesylerar(sitignalohcsuorbiF03-02
biopsies). 
Diagnosis more often based on findings of 
chronic cholestasis, ductopenia, ductular 
reaction and a “biliary pattern” of fibrosis. 
Approximately 25% have bridging fibrosis or 
cirrhosis by 5 years post-transplant. 
More frequently clinically symptomatic 
than recurrent PBC.  
Approximately 10% progress to graft 
failure. Histological and radiological 
features difficult to distinguish from 
ischaemic cholangiopathy. Diagnosis 
therefore requires exclusion of other 
causes of biliary tract disease. 
Autoimmune 
hepatitis (AIH) 
yrotammalfnihcir-llecamsalptcartlatroP03-02
infiltrate associated with interface hepatitis. 
Lobular inflammation frequently present -  
severe cases include foci of confluent/bridging 
necrosis.  
Lobular inflammatory changes may resemble 
“central perivenulitis” and can occur as the first 
manifestation of recurrent disease. 
Most cases occur as a result of 
suboptimal immunosuppression and 
respond to immunosuppressive 
therapy.  
Diagnosis based on a combination of 
biochemical, serological, and 
histological findings. 
Alcoholic liver 
disease (ALD) 
)sesacfo%06>(nommocegnahcyttaF03-01
Steatohepatitis and  fibrosis less common. 
Progression to cirrhosis rare. 
Recurrent alcohol consumption 
common, but serious graft 
complications are rare.  
Non-alcoholic 
Fatty Liver 
Disease (NAFLD) 
.)sesacfo%001-06(nommocegnahcyttaF04-02
 10-40% progress to steatohepatitis and up to 
12% become cirrhotic. 
Risk factors for NAFLD often persist 
and may be exacerbated by 
immunosuppressive drugs and other 
transplant-related factors. 
Many people with recurrent NAFLD 
have normal LFTs. 
(%)
Frontiers in Liver TransplantationChronic rejection (CR)
Classical cases of chronic rejection (CR), described in the late
1980s and early 1990s, were associated with ductopenia and an
obliterative arteriopathy, usually progressing to graft failure
within the ﬁrst 12 months of transplantation [1,27]. Improve-
ments in immunosuppression have resulted, not only in a
reduced prevalence of graft failure from CR (currently less than706 Journal of Hepatology 2011–2%), but also in a different pattern of presentation. More cases
now occur later (>12 months post transplant) with a more insid-
ious presentation and an indolent course, in some cases running
for a period of several years without progressing to graft failure
[6,49]. Histological features may also be different to those seen
in classical cases of chronic rejection. One important example is
the development of features of chronic cholestasis including a
ductular reaction and periportal ﬁbrosis [49], producing a ‘‘biliary1 vol. 55 j 702–717
JOURNAL OF HEPATOLOGY
pattern’’ resembling that seen in biliary obstruction. Late CR may
thus resemble changes seen in other chronic biliary diseases
associated with ductopenia in the liver allograft - these include
recurrent primary biliary cirrhosis (PBC), recurrent primary scle-
rosing cholangitis (PSC), and ischaemic cholangiopathy. Before
attributing changes to late CR, imaging of the biliary tree should
be carried out to exclude others cause of large duct disease,
including recurrent PSC. Features favouring a diagnosis of CR
include bile duct inﬂammation, senescence-related changes in
bile ducts (atrophy, nuclear pleomorphism, disordered polarity,
and cytoplasmic eosinophilia) [50], and the presence of CP [30].
In cases where there is a problem in the distinction between late
CR and recurrent biliary disease (PBC or PSC), review of previous
biopsies may help to identify CR as the more likely diagnosis.
Most cases of late CR will have one or more previous biopsies
showing features of acute rejection, often including prominent
bile duct injury and other features suggesting transition to early
chronic rejection. In some cases CP lesions may progress to cen-
trilobular ﬁbrosis and less commonly to the development of
bridging ﬁbrosis or cirrhosis. The latter typically has a veno-
centric pattern, which is probably related to rejection-induced
occlusive lesions in hepatic and portal veins [30,49]. In cases
where diagnostic histological features are lacking, knowledge of
the clinical context (e.g. suboptimal immunosuppression levels)
and review of preceding biopsies (which usually include one or
more specimens with AR) should help to identify CR as the most
likely cause for graft dysfunction.Disease recurrence
Recurrent disease is the commonest recognized cause of graft
dysfunction in patients surviving >12 months post-transplant. A
summary of the main diseases that recur in the liver allograft is
presented in Table 5. The prevalence and clinical signiﬁcance of
disease recurrence vary considerably. For some conditions (e.g.
hepatitis C), recurrence is common and has an important impact
on graft function and graft survival. Other diseases recur in aFig. 2. Recurrent hepatitis C with severe inﬂammatory activity. Liver biopsy 21 month
normal) shortly after antiviral therapy had been stopped because of nephric abscess. He
tract contains a moderately dense inﬁltrate of mononuclear inﬂammatory cells. This is n
moderate interface hepatitis. (B) There is prominent perivenular inﬂammation with con
Journal of Hepatology 201mild/subclinical form (e.g. PBC) or respond readily to treatment
(e.g. autoimmune hepatitis) and thus have little or no impact
on graft or patient survival.
There are a number of factors that inﬂuence histological
assessment of disease recurrence in the liver allograft
[1,27,51,52]. Histological features of some recurrent diseases
overlap with other complications of liver transplantation. The
most important example is hepatitis C and acute rejection. Other
examples are recurrent biliary disease (PBC, PSC) having overlap-
ping features with CR and recurrent PSC with ischaemic cholan-
giopathy. Interactions between recurrent disease and other
graft complications (e.g. hepatitis C and rejection) can produce
complex changes that are difﬁcult to interpret. The effects of
immunosuppression should also be considered. Viral infections
behave more aggressively in this setting – histological manifesta-
tions of this include more severe inﬂammatory activity and
more rapid progression to ﬁbrosis and cirrhosis or, in a small
number of cases, atypical cholestatic features (‘‘ﬁbrosing chole-
static hepatitis’’). By contrast immune-mediated diseases such
as autoimmune hepatitis (AIH) or PBC should be prevented from
recurring or progress more slowly when adequate levels of
immunosuppression are maintained, but may be ‘‘unmasked’’ if
immunosuppression is reduced for any reason.
The histological features of most recurrent diseases are similar
to those occurring in the native liver and will not be described in
detail here. Some of the main changes that are seen in biopsies
obtained >12 months post-LT are summarized in Table 5. For a
more detailed description of the pathology of recurrent disease,
the reader is referred elsewhere [1,27].
Recurrent hepatitis C
End-stage liver disease due to chronic HCV infection is the lead-
ing indication for transplantation in many centres. Re-infection is
universal and begins within a few hours of implanting the new
liver [53]. Most cases (>80%) develop graft inﬂammation related
to HCV, but the severity and clinical consequences of graft
re-infection are very variable [54].s post-transplant from a man who presented with acutely deranged LFTs (AST 15
became HCV-RNA positive, having previously been HCV-RNA negative. (A) Portal
ot associated with signiﬁcant inﬂammation of bile ducts or portal vessels. There is
ﬂuent hepatocyte necrosis (‘‘central perivenulitis’’).
1 vol. 55 j 702–717 707
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Histological features in biopsies obtained >12 months post-LT
are mostly similar to those that are seen with chronic HCV
infection in the native liver. There is typically a predominantly
portal-based mononuclear inﬂammatory inﬁltrate including lym-
phoid aggregates. Interface hepatitis and lobular inﬂammation
are usually mild in severity. Mild steatosis may also be present.
In addition to conﬁrming a diagnosis of recurrent HCV (and
excluding other causes of graft dysfunction), liver biopsies are
used to assess disease severity and progression. Histological
abnormalities are often present in protocol biopsies from HCV-
positive patients who are clinically well, with apparently normal
graft function [5,6] and the changes seen in these specimens may
have implications for prognosis and treatment [54]. For example,
the presence and severity of ﬁbrosis at one year have been shown
to be predictive for subsequent progression to cirrhosis and graft
failure [55–58] and this information may help to identify patients
who are most likely to beneﬁt most from anti-viral therapy [59].
Liver biopsies are also used to monitor treatment responses [60].
The scoring systems used for grading and staging HCV in the
native liver have also been applied to post-transplant biopsies.
However, they should be used cautiously in this setting, particu-
larly in cases with atypical features or the possibility of a dual
pathology (e.g. HCV and rejection).
Non-invasive markers are increasingly used to assess the
severity of HCV infection and monitor disease progression in
the native liver and have also more recently been used in a sim-
ilar manner in liver allograft recipients. These include serum bio-
markers and transient elastography, both of which have been
shown to reliably diagnose advanced ﬁbrosis in HCV-positive
patients [61,62] and to have predictive value in identifying
patients likely to progress rapidly to graft ﬁbrosis [63,64]. Cau-
tion should be applied to the interpretation of these non-invasive
tests in the transplant population, as there are other possible
causes of graft ﬁbrosis, but it is likely that they will lead to a
changing role for liver biopsy in the assessment of allograft dam-
age in HCV-positive patients.
There are three important differences that apply to the histo-
logical assessment of HCV in the liver allograft. Firstly, the dis-
ease tends to behave in a more aggressive manner. This may be
manifested by more severe inﬂammatory activity, sometimes
including areas of conﬂuent and bridging necrosis (Fig. 2),
which are very rarely seen with HCV infection in the non-
immunosuppressed person. In such cases, the possibility of an
additional cause for lobular necro-inﬂammation should be con-
sidered, the main ones being late rejection and de novo autoim-
mune hepatitis [30]. In cases where it is difﬁcult to make a
distinction between aggressive recurrent HCV and other causes
of lobular necro-inﬂammation (usually manifested as central
perivenulitis), knowledge of relevant clinical events may help
to identify the most likely cause (Fig. 2). For example, a recent
reduction in immunosuppression would favour a diagnosis of
rejection, whereas high viral RNA levels favour HCV as a more
likely cause for graft dysfunction. There is also more rapid pro-
gression to ﬁbrosis and cirrhosis – approximately 20–50% of
patients are cirrhotic 5–10 years post transplant [54,65]. Sec-
ondly, there may be atypical features, some of which reﬂect the
effects of immunosuppression – these include cholestatic fea-
tures resembling so-called ﬁbrosing cholestatic hepatitis (FCH),
ﬁrst described as a complication of HBV infection, and features
resembling autoimmune hepatitis. FCH mainly presents during
the ﬁrst few months after transplantation, when levels of immu-708 Journal of Hepatology 201nosuppression are highest [66,67]. It is rarely seen >12 months
post-LT and will not, therefore, be discussed further here. Thirdly,
there are important interactions with other graft complications,
particularly rejection – these may produce complex histological
changes that are difﬁcult to interpret.
HCV with ‘‘autoimmune features’’ (‘‘plasma cell hepatitis’’)
Recent studies have described biochemical, immunological, and
histological features resembling AIH in patients transplanted for
HCV. These have occurred in two main settings. Some have pre-
sented as a complication of anti-viral therapy with interferon
(IFN) and may represent an alloimmune response triggered by
IFN-induced stimulation of the host immune system [68–71].
The overall prevalence in the largest reported series was 20%
[70]. A similar mechanism has been postulated for the develop-
ment of rejection in HCV-positive patients following treatment
with IFN (discussed below). Other studies have documented his-
tological features suggestive of AIH unrelated to anti-viral ther-
apy in approximately 15% of patients with recurrent HCV
[72,73]. In addition to having plasma cell rich portal and lobular
inﬂammatory inﬁltrates – giving rise to the term ‘‘plasma cell
hepatitis’’ (PCH) [73] – most cases are associated with features
of central perivenulitis. Cases with autoimmune features have a
worse outcome than those with ‘‘typical’’ recurrent HCV. Whilst
some cases are associated with auto-antibodies and/or raised
serum IgG levels, supporting a diagnosis of AIH [72], others
appear to be related to suboptimal immunosuppression, suggest-
ing that these changes may represent a form of superimposed
rejection [73]. The presence of a plasma cell rich inﬁltrate in
the native liver of patients transplanted for HCV has recently
been identiﬁed as a risk factor for the subsequent development
of PCH, suggesting that some patients have an immunological
predisposition to develop PCH [74].
Hepatitis C and rejection
The relationship between HCV and rejection is complex. The
immunosuppressive therapy used to treat episodes of AR is an
important risk factor predisposing to more severe HCV infection
[75,76]. Conversely, a higher incidence of AR and CR has been
observed in HCV-positive patients compared with those trans-
planted for other disease [77–81]. This association probably
reﬂects a number of factors – these include different approaches
to immunosuppression in HCV-positive patients, shared path-
ways of immune-mediated damage between HCV and rejection
and the effects of anti-viral therapy, which may result both in
non-speciﬁc augmentation of the host’s immune system and
increased hepatocellular metabolism of immunosuppressive
drugs following viral clearance from hepatocytes [81–83].
The distinction between HCV infection and rejection as a
cause for graft dysfunction continues to be major problem clini-
cally. Non-invasive methods are not reliable in making the dis-
tinction and this, therefore, remains a common indication for
liver biopsy. Unfortunately, the two conditions also have overlap-
ping histological features, making the assessment of liver allo-
graft biopsies difﬁcult. Both conditions are characterised by
predominantly portal-based inﬂammation. Other features typi-
cally seen in acute rejection, which are also recognized to occur
with HCV infection in the native liver, are bile duct inﬂammation,
portal venous endothelitis, and portal tract eosinophilia [84,85],
although these changes are rarely more than mild in severity.
Features that are helpful in distinguishing recurrent HCV1 vol. 55 j 702–717
Table 6. Comparison of histological changes occurring in hepatitis C infection and acute cellular rejection of the liver allograft. (A) Portal and periportal changes;
(B) Lobular changes.
A
B
Hepatitis C Rejection 
Portal inflammation Mainly mononuclear cells 
(lymphoid aggregates) 
Mixed infiltrate 
(lymphocytes, macrophages, blast cells  
neutrophils, eosinophils)
Interface hepatitis Variable (generally mild) Usually mild 
Bile duct inflammation None/mild (lymphocytes) Variable, may be prominent (mixed infiltrate)
Bile duct loss None Variable (in cases progressing to chronic rejection)
Venous endothelial inflammation None/mild Variable, may be prominent 
Fibrosis Yes No (except in cases with chronic hepatitic features) 
Hepatitis C 
Generally mild 
Spotty 
Random 
Lobular disarray 
Rare (except FCH-like cases) 
Yes (macrovesicular) 
Common 
Rejection 
Variable 
Confluent 
Perivenular 
Hepatic vein endothelitis 
Common 
No 
Less numerous 
Lobular inflammation 
Severity 
Pattern 
Distribution 
Associated features 
Cholestasis 
Fatty change 
Acidophil bodies 
JOURNAL OF HEPATOLOGYhepatitis from rejection are summarized in Table 6. In most cases,
the time of occurrence and pattern of inﬂammation enable the
main cause of graft damage to be identiﬁed with a reasonable
degree of conﬁdence. Most episodes of AR occur during the ﬁrst
3 months of transplantation, a time at which portal inﬂammatory
changes related to recurrent HCV infection are unlikely to occur.
Conversely, AR is rare >12 months post-LT, whereas this is a time
at which portal hepatitis related to recurrent HCV is likely to be
present. A problem in the assessment of late biopsies from
HCV-positive patients concerns the possibility of late rejection
presenting with features of chronic hepatitis or central perivenu-
litis, both of which are discussed earlier.
Biopsies in which the distinction between HCV and AR is dif-
ﬁcult are likely to have changes reﬂecting a combination of both
conditions [86,87] (Fig. 3). In the majority of such cases, rejec-
tion-related changes are mild in severity – recurrent HCV is best
regarded as the primary diagnosis and anti-rejection therapy is
not indicated [87,88]. Increased immunosuppression should only
be considered as a treatment option if AR is at least moderate in
severity, or if there are features suggesting progression to CR.
Immunohistochemical studies have also been used in the dif-
ferential diagnosis between hepatitis C and rejection. These
include staining for HCV antigens as a marker of HCV infection
[89–91], C4d as a marker of rejection [92–94], hepatocellular
expression of the interferon-inducible MxA protein as a marker
of chronic HCV infection [95], and the cell-cycle protein mini-
chromosome maintenance (mcm) protein mcm-2 to identify
the rate of proliferation in portal lymphocytes (higher in rejection
than HCV) [96]. Some of these approaches may help to identifyJournal of Hepatology 201the main cause of graft damage in cases where routine histolog-
ical ﬁndings are inconclusive [89,96].De novo disease
This term has been used to describe patients who are transplanted
for one type of primary liver disease and subsequently develop
features suggesting a different primary liver disease. A number
of diseases listed in Table 5 can develop de novo following liver
transplantation. This applies to viral infection (hepatitis B and
C), which may be acquired from the donor liver or other sources,
AIH and non-alcoholic fatty liver disease (NAFLD). Histological
features are generally similar to those seen in recurrent disease.
De novo autoimmune hepatitis
The most important example of de novo disease is de novo AIH.
Numerous studies have described classical biochemical, immu-
nological, and histological features of AIH developing in patients
transplanted for other diseases [35,43,97–106]. A higher fre-
quency has been reported in children (5–10%) compared with
adults (1–2%), possibly related to immunosuppressive drugs
interfering with normal T cell maturation in the immature
immune system. Most cases present >1 year post-LT and respond
well to increased immunosuppression, but some have progressed
to cirrhosis or graft failure. Histological features closely resemble
those occurring with AIH in the native liver and recurrent AIH in
the liver allograft. They include a plasma-cell rich mononuclear1 vol. 55 j 702–717 709
Fig. 3. Features in keeping with recurrent hepatitis C and rejection. Liver biopsy 3 years post-transplant from an HCV-positive patient who presented with a raised AST
(7 normal) (A) Features compatible with mild chronic hepatitis C include portal tracts with a light inﬁltrate of mononuclear inﬂammatory cells, lymphoid aggregate
formation, mild interface hepatitis, and mild steatosis. Additional features suggesting the presence of co-existent rejection are (B) prominent bile duct injury (arrow), (C)
portal vein endothelitis (arrows), and (D) small foci of central perivenulitis.
Frontiers in Liver Transplantationportal inﬂammatory inﬁltrate associated with varying degrees of
interface hepatitis (Fig. 4). Lobular inﬂammation and necrosis
tend to be more prominent than in the native liver [98,100]
and can include features of central perivenulitis [30]. It is worth
noting that autoantibodies are frequently present without signs
of graft dysfunction, particularly in the paediatric population
[35,102,107], and liver biopsy is, therefore, required to determine
the nature of any damage present.
Many studies have identiﬁed overlapping areas between
de novo AIH and rejection – these include autoantibodies being
present, sometimes transiently, in otherwise typical episodes of
rejection (acute and chronic) [35,102,108,109], previous acute
rejection episodes being a risk factor for the development of de
novo AIH [43,99,104] and, as discussed earlier, features of de novo
AIH arising in the setting of under-immunosuppression [73] or
when the recipient’s immune system is stimulated by anti-viral
treatment with interferon [68–71]. Perhaps the most convincing
evidence for an alloimmune response has come from two Spanish
groups, who both found that the de novo AIH occurred exclusively
in glutathione-S-transferase T1 (GSTT1) negative recipients of a710 Journal of Hepatology 201GSTT1-positive donor liver and was associated with the develop-
ment of donor-speciﬁc anti-GSTT1 antibodies [100,101,103,105].
As the GSTT1 enzyme is expressed by hepatocytes in GSTT1-
positive individuals, the development of de novo AIH in the
setting of a donor/recipient mismatch for GSST1 may thus repre-
sent a form of late rejection, in which immune-mediated injury is
mainly directed towards hepatocytes [17]. However, some stud-
ies have failed to demonstrate anti-GSST1 antibodies as an
important factor in the development of de novo AIH [110–112]
– such cases may be associated with the development of auto-
antibodies directed towards other potential target antigens
expressed by hepatocytes. Examples include, antibodies to
cytokeratin 8/18 [110] and atypical LKM antibodies to carbonic
anhydrase III or subunit beta1 of proteasome [113]. The de novo
development of antibodies to the bile salt export pump (BSEP)
protein, in children who became cholestatic following transplan-
tation for BSEP deﬁciency, can likewise be regarded as an
alloimmune response to BSEP proteins expressed in the canaliculi
of the liver allograft [114–116]. The distinction between
alloimmune and autoimmune responses becomes blurred with1 vol. 55 j 702–717
Fig. 4. Chronic hepatitis with features suggesting a diagnosis of de novo autoimmune hepatitis. Liver biopsy 2 years post-transplant from a patient transplanted for
metastatic gastrointestinal stromal tumour, who developed abnormal LFTs (AST 2 normal). (A) A portal tract contains a dense plasma cell rich inﬂammatory inﬁltrate
associated with interface hepatitis. (B) A similar inﬁltrate is present in a perivenular region where it is associated with features of central perivenulits. The patient was
subsequently found to have autoantibodies and a raised serum IgG.
Table 7. Causes of chronic hepatitis in the liver allograft.
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JOURNAL OF HEPATOLOGYtime following transplantation – whilst early acute rejection epi-
sodes are MHC-restricted and epitope speciﬁc, the resultant graft
damage may lead to T cell responses to other graft antigens
occurring in a non-MHC restricted fashion and may also break
tolerance to self antigens, thus allowing the development of auto-
immune responses [117,118].
De novo non-alcoholic fatty liver disease (NAFLD)
The distinction between recurrent and de novo NAFLD is often dif-
ﬁcult. Liver transplant patients are at risk for developing a number
of features of the metabolic syndrome, such as diabetes mellitus,
weight gain, hypertension, and hyperlipidaemia and are thus pre-
disposed to the development of NAFLD [119,120]. Steatosis in the
donor liver has also been identiﬁed as a risk factor for the devel-
opment of steatosis in late post-transplant biopsies, although
the mechanism for this is uncertain [121]. Several studies have
identiﬁed cases of NAFLD, which appear to have arisen de novo fol-
lowing liver transplantation [119,121–126]. However, some of
these have occurred in patients whowere transplanted for crypto-
genic cirrhosis and/or had risk factors for the metabolic syndrome
prior to transplantation and could thus be regarded as having
recurrent rather than de novo disease [119,122,123,125,127].
Interactions between hepatitis C infection, insulin resistance,
and NAFLD also appear to be important in the pathogenesis of
recurrent HCV and de novo NAFLD [126,128–131].
Fatty change, apparently unrelated to recurrent disease, is pres-
ent in 18–40% of post-transplant biopsies [7,120,121,125,126] and
is also a common ﬁnding in protocol biopsies obtained from
patientswith normal liver function tests (LFTs) [7,9,121]. Steatosis
is mainly macrovesicular and usually mild in severity. Features of
steatohepatitis, also typicallymild in severity, are present in1–13%
of cases. Perisinusoidal ﬁbrosiswas present in 29% of patientswith
de novoNAFLD in one study [121] – however, this lesion is difﬁcult
to assess in the liver allograft as a similar pattern of ﬁbrosis may
also occur as part of the spectrumof ‘‘hepatic structural abnormal-
ities’’, which are discussed later. More severe ﬁbrosis is unusual,
but occasional cases have progressed to cirrhosis.Journal of Hepatology 201Other histological ﬁndings in late post-transplant biopsies
Idiopathic post-transplant hepatitis (IPTH)
The terms ‘‘idiopathic chronic hepatitis’’ or IPTH, have been used
to describe cases with histological features of chronic hepatitis
that are not obviously related to recognized cause of chronic graft
hepatitis, such as chronic viral infection or autoimmune hepatitis
(recurrent or de novo) (Table 7). The reported frequency varies
considerably, possibly reﬂecting a number of factors that have
been discussed earlier (Table 4). The variable terminology used
to describe unexplained inﬂammatory changes in late post-
transplant biopsies may account for at least some of the apparent
discrepancies between individual centres. Other terms used in
this context include ‘‘portal/parenchymal mononuclear
inﬂammation’’ [132], ‘‘portal lymphocytic inﬂammation’’ [133],
‘‘non-speciﬁc inﬂammation’’ [134], ‘‘graft inﬂammation’’ [14],
‘‘interface hepatitis’’ [135], and ‘‘non-speciﬁc hepatitis’’ [10].
Overall, it has been estimated that features compatible with a
diagnosis of IPTH can be observed in 10–50% of patients undergo-
ing protocol biopsy >1 year post-transplant [16] and up to 60% of1 vol. 55 j 702–717 711
Fig. 5. ‘‘Idiopathic’’ post-transplant chronic hepatitis. Liver biopsy 9 years post-transplant from a patient who underwent liver transplantation for cystic ﬁbrosis at the
age of 13 years. (A) Portal tract contains a moderately dense inﬁltrate of mononuclear inﬂammatory cells, not associated with typical features of acute or chronic rejection.
An area of lobular inﬂammation is associated with central-portal bridging necrosis. (B) There is ﬁbrous portal expansion with bridging ﬁbrosis (Haematoxylin Van Gieson).
Frontiers in Liver Transplantationchildren at 10 years [12], making this the commonest overall
diagnosis in annual review biopsies from adults [136] and chil-
dren [12] in some centres. The prevalence increases with time
– ranging from 20% to 30% during the ﬁrst 3 years post-transplant
to more than 60% at 10 years [12,14,135,137]. Most patients with
‘‘idiopathic’’ CH are clinically well with good graft function.
Minor abnormalities of liver biochemistry may be present, usu-
ally a mild elevation in serum transaminases. Within the range
of normal LFTs, the histological severity of hepatitis appears to
correlate with serum alanine transaminase (ALT) levels [10].
Histological ﬁndings include a predominantly mononuclear
portal inﬂammatory inﬁltrate, which lacks typical features of
acute or chronic rejection and is associated with variable inter-
face hepatitis (Fig. 5A). Lobular inﬂammatory changes are com-
monly present – they tend to be most marked in perivenular
regions and may be associated with foci of conﬂuent or bridging
necrosis, resembling CP [30]. Recent studies have shown that
chronic hepatitis unrelated to disease recurrence frequently leads
to the development of ﬁbrosis in the paediatric population, with
50–70% of children progressing to bridging ﬁbrosis or cirrhosis by
10 years post-LT [12,14,135] (Fig. 5B). Progression to bridging
ﬁbrosis or cirrhosis has also been observed in up to 27% of adults
with unexplained CH [137,138].
Many paediatric cases are associated with the development of
autoantibodies [12] or uncharacterized serum factors reacting
with normal hepatocytes and/or biliary epithelial cells [139] or
with features suggestive of rejection [135], suggesting that this
is likely to represent a form of immune-mediated graft damage.
This hypothesis is supported by the observation that treatment
of IPTH with increased immunosuppression may prevent ﬁbrosis
progression [140] and by the suggestion, discussed earlier, that
late rejection may present with ‘‘hepatitic features’’ resembling
chronic viral or autoimmune hepatitis. In cases of IPTH associated
with auto-antibodies, a diagnosis of de novo AIH should be con-
sidered – however, many such cases have normal or only mildly
elevated transaminase levels and do not thus fulﬁl the diagnostic
criteria for de novo AIH [12]. Nevertheless, these observations
provide further support for the concept that late rejection, de712 Journal of Hepatology 201novo AIH and IPTH may all be part of an overlapping spectrum
of (allo)immune damage in the long-term liver allograft.
Before making a diagnosis of IPTH, other causes of chronic
hepatitis in the liver allograft should be excluded (Table 7).
Recognised viral agents, such as hepatitis B and C, cannot be iden-
tiﬁed in the great majority of patients who have graft hepatitis
following liver transplantation for non-viral liver disease. A
recently postulated cause of late graft inﬂammation is hepatitis
E virus (HEV) infection, which has been suggested to lead to
chronic hepatitis in the setting of immunosuppression and in a
small number of cases to the development of severe ﬁbrosis or
cirrhosis [141–144]. Most cases appear to represent acquired
infection and may be related to the consumption of inadequately
cooked game meat or pork [145]. Treatment by reducing immu-
nosuppression [144] or by giving anti-viral therapy [146] has
proved to be effective in some cases. However, the functional sig-
niﬁcance of HEV infection has been questioned by studies show-
ing that HEV seropositivity is present with a similar frequency in
non-transplant patients with chronic liver disease [143] and in
healthy adults with no evidence of liver disease [147]. A higher
than expected frequency of unexplained chronic hepatitis has
been seen in patients transplanted for acute liver failure due to
seronegative hepatitis [138,148] – the reason for this is uncertain,
but one possible explanation might be an unidentiﬁed viral agent.
Features of a ‘‘non-speciﬁc’’ chronic hepatitis can occur as an
early manifestation of recurrent autoimmune diseases, such as
AIH [149], PBC [150], and PSC [151], in some cases preceding
the development of more typical diagnostic features by several
years.
Other causes of graft ﬁbrosis
There are other possible mechanisms of late graft ﬁbrosis, partic-
ularly in the paediatric population. Centrilobular ﬁbrosis has
been identiﬁed in 10–20% of late post-transplant biopsies from
children, sometimes as an isolated ﬁnding [11,152], and most
likely represents organization of rejection-related central perive-
nulitis lesions.1 vol. 55 j 702–717
Fig. 6. Nodular regenerative hyperplasia. (A) Protocol liver biopsy 1 year post-transplant from a patient transplanted for Wilson disease. Two hyperplastic hepatocyte
nodules are separated by a zone in which cell plates are compressed (Reticulin stain). (B) Perisinusoidal ﬁbrosis is present at the periphery of a hyperplastic nodule
(Haematoxylin Van Gieson).
JOURNAL OF HEPATOLOGYPortal ﬁbrosis has been observed as an isolated ﬁnding in late
biopsies from children [15,153,154]. The prevalence and severity
increase with time – by 10 years ﬁbrosis was present in 69% of
children biopsied, of whom >50% had bridging ﬁbrosis or cirrho-
sis [15]. Graft ﬁbrosis in these cases was not associated with
inﬂammatory changes supporting a diagnosis of chronic hepatitis
or rejection, but instead with transplant-related factors predis-
posing to biliary complications [15]. A biliary pattern of ﬁbrosis
had been observed in an earlier study of the same cohort of
patients [153].
Hepatic structural abnormalities
Hepatic structural abnormalities are seen in 20–30% of biopsies
obtained >5 years post-transplant [3,4,6155,156]. The most com-
mon manifestation is nodular regenerative hyperplasia (Fig. 6A).
Other observed changes include liver cell plate disarray, perisinu-
soidal ﬁbrosis (Fig. 6B), hepatocellular atrophy, and sinusoidal
dilatation/congestion. Possible causes include vascular problems
(particularly portal venous insufﬁciency), drug toxicity (e.g. aza-
thioprine) or immune-mediated damage to sinusoidal and/or
vascular endothelial cells. Many cases are observed in protocol
biopsies and have no obvious clinical manifestations [3,6], but
some patients develop signs of portal hypertension [155] and a
few have progressed to graft failure necessitating retransplanta-
tion [4,157]. A higher prevalence of nodular changes has been
observed in late biopsies from reduced size allografts – this
may relate to disturbances to the hepatic micro-architecture that
occur following restoration of liver volume in these cases [158].
Role of liver biopsy in graft monitoring and treatment
Much of the foregoing discussion has focused on the concept that
otherwise unexplained inﬂammatory changes in late post-trans-
plant biopsies are likely to have an alloimmune basis, particularly
in the paediatric population, and have the potential to progress to
graft ﬁbrosis or cirrhosis. The fact that these changes are fre-
quently seen in protocol biopsies from patients who are clinically
well with normal LFTs suggests that protocol biopsies have an
important role in identifying subclinical graft dysfunction inJournal of Hepatology 201patients surviving long-term following liver transplantation
[9,28]. They should probably also prompt a low threshold for
autoantibody testing, particularly in children.
On the other hand, many patients undergoing late post-trans-
plant protocol biopsy have minimal or mild inﬂammatory
changes with no signiﬁcant ﬁbrosis. Can it be argued that these
ﬁndings might indicate a form of graft tolerance and, if so, could
they be used to identify patients in whom immunosuppression
might be safely reduced or withdrawn? In a recent review of
235 protocol biopsies obtained >1 year post-LT from patients
with normal LFTs, biopsy-directed changes in immunosuppres-
sion were instigated in 32% of cases [9]. In 76% of the cases where
a change was made, immunosuppression was reduced – usually
based on lack of inﬂammation in a patient where there were con-
cerns about renal impairment.
Liver biopsies are also used routinely in the assessment and
monitoring of patients undergoing immunosuppression with-
drawal in an attempt to induce ‘‘operational tolerance’’. The
majority of studies have been carried out on patients with stable
graft function, usually at least 2 years post-transplant, with over-
all success rates in the region of 10–20% (reviewed by Demetris
[23] and Sanchez-Fueyo [159]). A higher frequency of successful
weaning of immunosuppression has been observed in the
paediatric population [160], particularly in young children
[161], possibly reﬂecting the immature immune system in
children. Pre-weaning biopsies are mainly used to exclude the
presence of rejection, but may also be able to identify other
features that are predictive of tolerance – examples include the
absence of signiﬁcant portal inﬂammation [19], lack of lobular
CD3+ and CD8+ T cells [19], lack of ﬁbrosis (in HCV-positive
patients [20]), and the presence of portal T cells with a regulatory
phenotype (FoxP3-positive) [21,162]. Studies on peripheral blood
samples have also attempted to identify markers associated with
a ‘‘tolerogenic proﬁle’’ [159] – examples include increased num-
bers of regulatory T cells (CD4+, CD25+, FoxP3+) and delta1 T cells,
decreased numbers of NK cells and alterations in the ratio of
dendritic cell subsets. Oligonucleotide microarrays and bioinfor-
matics have also been used to identify more complex tolerance-
related gene expression proﬁles (reviewed by Sanchez-Fueyo
[159]). Post-weaning biopsies have been used, both to investigate1 vol. 55 j 702–717 713
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the cause of graft dysfunction (usually rejection) and on a proto-
col basis. Most episodes of AR occurring in this setting are mild
and respond to treatment with re-instating immunosuppression.
Some studies have identiﬁed bile duct atypia/atrophy and/or
focal duct loss raising the possibility of progression to early CR
[20,21,163], including protocol biopsies from patients with nor-
mal liver tests. Protocol biopsies have also shown more severe
periportal ﬁbrosis in patients who are operationally tolerant
compared with those maintained on immunosuppression
[21,22] – it has been postulated that this may reﬂect a pro-
ﬁbrogenic role for portal tract T lymphocytes with a regulatory
phenotype, which are also present in such cases [22,164]. How-
ever, the fact that reinstatement of immunosuppressive therapy
has resulted in reducing the severity of ﬁbrosis in apparently
tolerant patients suggests that such patients may in fact have a
low-grade subclinical form of rejection [22].Conclusions and future developments
The majority of patients surviving long-term following liver
transplantation have allografts that are histologically abnormal.
Many of these abnormalities have been observed in protocol
biopsies from people who appear to be well with good graft
function. Uncertainties relating to the pathogenesis and clinical
signiﬁcance of many of the pathological changes that are seen
in this setting have led to many centres reducing or discontinuing
protocol biopsies. The role of protocol biopsies in assessing dis-
ease severity, such as ﬁbrosis progression in recurrent hepatitis
C, is also changing with the increasing use of non-invasive
methods to assess liver ﬁbrosis. Nevertheless, there is emerging
evidence to suggest that protocol biopsies may reveal clinically
important changes, such as graft ﬁbrosis and cirrhosis, particu-
larly in the paediatric population. Furthermore, some of these
changes are likely to reﬂect the consequences of prolonged
inﬂammation related to subclinical alloimmune injury and may,
therefore, have implications for maintaining or increasing immu-
nosuppressive therapy. Conversely, the absence of signiﬁcant
inﬂammation or ﬁbrosis in a late protocol biopsy may help to
identify patients in whom immunosuppression can be safely
reduced or even withdrawn completely in the hope of achieving
‘‘operational tolerance’’. Further studies are required to devise
optimal algorithms for the use of liver biopsy in the assessment
of the long-term liver allograft.Conﬂict of interest
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